BioCentury | Mar 3, 2017
Company News

Otsuka acquiring ADHD company Neurovance

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire ADHD play Neurovance Inc. (Cambridge, Mass.) for $100 million up front and up to $150 million in milestones. The deal gives Otsuka rights to centanafadine (CFR; EB-1020...
BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

Stimulants are the most effective drugs for ADHD, but the very things that make them effective - blocking norepinephrine and dopamine reuptake - can also lead to addiction and cause anxiety. Neurovance Inc .'s lead candidate for...
BioCentury | Apr 14, 2014
Finance

Globe spinning

Globe spinning Australian pain play Spinifex Pharmaceuticals Pty. Ltd. is looking to tap into Northern Hemisphere capital with its $45 million series C round and the establishment of a U.S. base. Last week's tranched round...
BioCentury | Apr 14, 2014
Financial News

Spinifex completes venture financing

Spinifex Pharmaceuticals Pty. Ltd. , South Yarra, Australia Business: Neurology Date completed: 4/10/14 Type: Venture financing Raised: Not disclosed Investors: Novo A/S; Canaan Partners; GBS Venture Partners; Brandon Capital Partners; UniSeed; UniQuest Note: The company raised...
BioCentury | Apr 11, 2014
Financial News

Pain play Spinifex secures $45 million series C

Spinifex Pharmaceuticals Pty. Ltd. (South Yarra, Australia) raised an undisclosed amount in a tranched $45 million series C round led by new investor Novo A/S. New investor Canaan Partners also participated along with existing investors...
BioCentury | Apr 7, 2014
Financial News

Neurovance financial update

Neurovance raised $6.3 million in an extension of a series A-1 round, bringing the total raised in the round to $13.3 million. All existing investors participated, including Novartis Venture Funds; Venture Investors; H&Q Healthcare Investors;...
BioCentury | Feb 17, 2014
Company News

Principia Biopharma management update

Principia Biopharma Inc. , South San Francisco, Calif. Business: Cancer, Autoimmune Hired: Christopher Chai as CFO, formerly SVP and CFO of Map Pharmaceuticals Inc., which Allergan Inc. acquired; and Steven Gourlay as CMO, formerly partner at...
BioCentury | Oct 22, 2012
Finance

Maximizing depression

Maximizing depression Euthymics Bioscience Inc. thinks spinning out its early stage assets into Neurovance Inc. will make it easier to partner Euthymics' lone remaining asset - its amitifadine candidate for depression. The two companies will have...
BioCentury | Oct 22, 2012
Financial News

Neurovance completes venture financing

Neurovance Inc. , Cambridge, Mass. Business: Neurology Date completed: 10/18/12 Type: Venture financing Raised: $7 million Investors: Novartis Venture Funds; Venture Investors; H&Q Healthcare Investors; H&Q Life Science Investors; GBS Venture Partners; State of Wisconsin Investment...
BioCentury | Oct 19, 2012
Company News

Euthymics' Neurovance spinout raises $7M

Neurovance Inc. (Cambridge, Mass.) emerged Thursday as a spinout of Euthymics Bioscience Inc. (Cambridge, Mass.) with $7 million raised in a series A round. Existing Euthymics investors financed the Neurovance round, including lead investor Novartis...
Items per page:
1 - 10 of 48
BioCentury | Mar 3, 2017
Company News

Otsuka acquiring ADHD company Neurovance

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire ADHD play Neurovance Inc. (Cambridge, Mass.) for $100 million up front and up to $150 million in milestones. The deal gives Otsuka rights to centanafadine (CFR; EB-1020...
BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

Stimulants are the most effective drugs for ADHD, but the very things that make them effective - blocking norepinephrine and dopamine reuptake - can also lead to addiction and cause anxiety. Neurovance Inc .'s lead candidate for...
BioCentury | Apr 14, 2014
Finance

Globe spinning

Globe spinning Australian pain play Spinifex Pharmaceuticals Pty. Ltd. is looking to tap into Northern Hemisphere capital with its $45 million series C round and the establishment of a U.S. base. Last week's tranched round...
BioCentury | Apr 14, 2014
Financial News

Spinifex completes venture financing

Spinifex Pharmaceuticals Pty. Ltd. , South Yarra, Australia Business: Neurology Date completed: 4/10/14 Type: Venture financing Raised: Not disclosed Investors: Novo A/S; Canaan Partners; GBS Venture Partners; Brandon Capital Partners; UniSeed; UniQuest Note: The company raised...
BioCentury | Apr 11, 2014
Financial News

Pain play Spinifex secures $45 million series C

Spinifex Pharmaceuticals Pty. Ltd. (South Yarra, Australia) raised an undisclosed amount in a tranched $45 million series C round led by new investor Novo A/S. New investor Canaan Partners also participated along with existing investors...
BioCentury | Apr 7, 2014
Financial News

Neurovance financial update

Neurovance raised $6.3 million in an extension of a series A-1 round, bringing the total raised in the round to $13.3 million. All existing investors participated, including Novartis Venture Funds; Venture Investors; H&Q Healthcare Investors;...
BioCentury | Feb 17, 2014
Company News

Principia Biopharma management update

Principia Biopharma Inc. , South San Francisco, Calif. Business: Cancer, Autoimmune Hired: Christopher Chai as CFO, formerly SVP and CFO of Map Pharmaceuticals Inc., which Allergan Inc. acquired; and Steven Gourlay as CMO, formerly partner at...
BioCentury | Oct 22, 2012
Finance

Maximizing depression

Maximizing depression Euthymics Bioscience Inc. thinks spinning out its early stage assets into Neurovance Inc. will make it easier to partner Euthymics' lone remaining asset - its amitifadine candidate for depression. The two companies will have...
BioCentury | Oct 22, 2012
Financial News

Neurovance completes venture financing

Neurovance Inc. , Cambridge, Mass. Business: Neurology Date completed: 10/18/12 Type: Venture financing Raised: $7 million Investors: Novartis Venture Funds; Venture Investors; H&Q Healthcare Investors; H&Q Life Science Investors; GBS Venture Partners; State of Wisconsin Investment...
BioCentury | Oct 19, 2012
Company News

Euthymics' Neurovance spinout raises $7M

Neurovance Inc. (Cambridge, Mass.) emerged Thursday as a spinout of Euthymics Bioscience Inc. (Cambridge, Mass.) with $7 million raised in a series A round. Existing Euthymics investors financed the Neurovance round, including lead investor Novartis...
Items per page:
1 - 10 of 48